Miraculins Pre-Eclampsia Markers

CONDITION ADDRESSED: Pre-Eclampsia

Diagnostic
Diagnostic
  • PREVENTION
  • DIAGNOSTIC
  • TREATMENT

CONTACT INFORMATION

Organization

Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto

Individual Contact

Dr. Isabella Caniggia

Application

  • Dual use in developed and developing countries

 

Advantages

  • First major development of a reliable biomarker diagnostic that can accurately predict the onset of PE
  • The collection of biomarkers developed by Miraculins has shown evidence of its ability to diagnose the disease in its earliest stages 

 

 

Important Milestones Achieved

  • Initial R&D conducted at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto
  • Licensed to Miraculins Inc. for further development and commercialization
  • Patent issued in July called "Methods for Early Diagnosing of an Increased Risk of Preeclampsia"
  • Highlighted in Maternova's Health Innovations portfolio 

 

Proposed Next Steps in Development

  • Further R & D required before commercialization and dissemination 

 

Partnerships/Collaboration Network

  • Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto
  • Miraculins Inc.
  • Maternova 

Stage of Development

Early R&D

Funding Source

Commercialization license in place